Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment

Aleix Prat, MD, PhD
Published Online: Thursday, Dec 15, 2016



Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response (pCR) to targeted treatment in patients with HER2-positive, hormone receptor (HR)-positive breast cancer.

HER2-positive breast cancer is defined by immunohistochemistry and fluorescence in situ hybridization, but the disease is heterogenous, Prat explains. Prior studies defined 4 intrinsic subtypes of the disease. One of them, HER2-enriched, suggests that it has the highest activation of the HER2 pathway. The prospective PAMELA trial treated 151 HER2-posiitve patients with trastuzumab (Herceptin), lapatinib (Tykerb), and endocrine therapy if the patient was also HR-positive. After 18 weeks, patients underwent surgery.

Results showed that the overall pCR rate was 30%. Among the HER2-enriched subtype, the pCR rate increased to 40.6%. In the non-enriched HER2 subgroup, the pCR rate was 10%. This shows that for patients with the HER2-enriched subtype, there is a high likelihood they will elicit a pCR with HER2-targeted agents, Prat says. This could lead to further reseach that will evaluate the activity of these patients on de-escalating treatment regimens, such as chemotherapy.
 


Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response (pCR) to targeted treatment in patients with HER2-positive, hormone receptor (HR)-positive breast cancer.

HER2-positive breast cancer is defined by immunohistochemistry and fluorescence in situ hybridization, but the disease is heterogenous, Prat explains. Prior studies defined 4 intrinsic subtypes of the disease. One of them, HER2-enriched, suggests that it has the highest activation of the HER2 pathway. The prospective PAMELA trial treated 151 HER2-posiitve patients with trastuzumab (Herceptin), lapatinib (Tykerb), and endocrine therapy if the patient was also HR-positive. After 18 weeks, patients underwent surgery.

Results showed that the overall pCR rate was 30%. Among the HER2-enriched subtype, the pCR rate increased to 40.6%. In the non-enriched HER2 subgroup, the pCR rate was 10%. This shows that for patients with the HER2-enriched subtype, there is a high likelihood they will elicit a pCR with HER2-targeted agents, Prat says. This could lead to further reseach that will evaluate the activity of these patients on de-escalating treatment regimens, such as chemotherapy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Assessing the Clinical Potential for Immunotherapies in the Treatment of Breast CancerFeb 22, 20171.0
Cancer Summaries and Commentaries™: Updates from Singapore: Advances in Personalized Lung Cancer TreatmentFeb 28, 20171.5
Publication Bottom Border
Border Publication